| Identification | Back Directory | [Name]
2H-1-Benzopyran-2-one, 3-(2-benzoxazolyl)-7-(diethylamino)-6-methyl- | [CAS]
2414374-41-5 | [Synonyms]
EMI56
2H-1-Benzopyran-2-one, 3-(2-benzoxazolyl)-7-(diethylamino)-6-methyl- | [Molecular Formula]
C21H20N2O3 | [MDL Number]
MFCD32878254 | [MOL File]
2414374-41-5.mol | [Molecular Weight]
348.4 |
| Chemical Properties | Back Directory | [Boiling point ]
550.0±60.0 °C(Predicted) | [density ]
1.259±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (143.51 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
3.47±0.20(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Biological Activity]
EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants[1].
EMI56 inhibits EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. EMI56 can be used in the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC)[1].EMI56 (10, 15, 20 μM; 2 h of treatment) strongly inhibits total EGFR levels, activation and downstream signaling in PC9 EGFR ex19del/T790M/C797S cells[1]. | [References]
[1]. Punit Saraon, et al. A Drug Discovery Platform to Identify Compounds That Inhibit EGFR Triple Mutants.Nat Chem Biol. 2020 May;16(5):577-586. |
|
|